Latest clinical updates | Hospital Healthcare Europe

This website is intended for healthcare professionals only.

Clinical

Positive opinion for tivozanib for the first-line treatment of advanced renal cell carcinoma in the EU

Positive opinion for tivozanib for the first-line treatment of advanced renal cell carcinoma in the EU

Sarilumab approved for the treatment of moderately to severely active rheumatoid arthritis in adults

Sarilumab approved for the treatment of moderately to severely active rheumatoid arthritis in adults

Survey reveals burden of myeloproliferative neoplasms on daily activity and ability to work

Survey reveals burden of myeloproliferative neoplasms on daily activity and ability to work

Data support the efficacy and safety of biosimilar rituximab in autoimmune disease and oncology

Data support the efficacy and safety of biosimilar rituximab in autoimmune disease and oncology

Coordinate My Care: enabling patient choice when it matters most

New radiopharmaceutical offers next-generation standard of diagnosis

New radiopharmaceutical offers next-generation standard of diagnosis

$New study illustrates large treatment gap in post-fracture care management$

New study illustrates large treatment gap in post-fracture care management

New study investigates the clinical utility of ORi™, Masimo Oxygen Reserve Index™

Sepsis screening in the emergency department

Breakthrough in detection of cancers

DePuy Synthes and Ethicon showcase intraoperative solutions aimed at reducing surgical site infections

DePuy Synthes and Ethicon showcase intraoperative solutions aimed at reducing surgical site infections

ATTUNE® Knee System four-year revision rate is lower than total knee class

Masimo and Mdoloris announce Masimo Open Connect™ (MOC) partnership

Olaparib maintenance therapy offers sustained quality of life and improved progression-free survival

Olaparib maintenance therapy offers sustained quality of life and improved progression-free survival

Nusinersen approved in the EU as first treatment for spinal muscular atrophy

Nusinersen approved in the EU as first treatment for spinal muscular atrophy

Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA

Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA

NICE publishes recommendation for everolimus in final draft guidance

NICE publishes recommendation for everolimus in final draft guidance

New FIT diabetes injection ‘Golden Rules’

New FIT diabetes injection ‘Golden Rules’

x